Company / Cash & Equivalents
Zivo Bioscience, Inc. Cash & Equivalents History
FY2013-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.8M
FY2022
5-year range
$137.9K / $8.9M
FY2018-FY2022
Trend
-79.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $1,383 in FY2015 to $9M in FY2021.
Based on SEC 10-K filings.
$2M in FY2022 with a 3-year CAGR of +73.2%.
Improved from $137,862 to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +73.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +73.2%, indicating consistent growth.
- In FY2022, cash & equivalents decreased 79.8% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -96.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $1.8M | -79.8% |
| FY2021 | $8.9M | +6357.1% |
| FY2020 | $137.9K | -60.2% |
| FY2019 | $346.1K | -31.7% |
| FY2016 | $507.0K | +36558.4% |
| FY2015 | $1.4K | +0.0% |
| FY2014 | $1.4K | -97.1% |
| FY2013 | $47.1K | +0.0% |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026